share_log

Earnings Call Summary | Ultragenyx Pharmaceutical(RARE.US) Q1 2024 Earnings Conference

Futu News ·  May 3 22:03  · Conference Call

The following is a summary of the Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript:

Financial Performance:

  • Ultragenyx reported Q1 2024 revenue of $109 million, with substantial contributions from Crysvita ($83 million) and smaller inputs from Dojolvi ($16 million) and Mepsevii ($7 million).

  • The company ended the quarter with $569 million in cash, cash equivalents and marketable securities.

  • In Q1, net cash used in operations amounted to $191 million.

  • The company projected total revenue for 2024 to be between $500 million and $530 million, marking a 15% to 22% growth from 2023.

Business Progress:

  • Ultragenyx presented positive data from their UX-111 gene therapy in Sanfilippo syndrome at the World Symposium meeting and confirmed benefits of their GTX-102 treatment for Angelman patients.

  • The company completed enrollment for their Phase II/III Orbit study and Phase III COSMIC study in osteogenesis imperfecta and proceeded with preparations for multiple Biologics License Application filings.

  • They continue collaborating with the FDA on their Angelman phase II studies and finalising the GTX-102 Phase III trial design.

  • The company successfully added more patients for Dojolvi and eagerly share plans for reporting top line Phase III DTX401 data, and progressing the setrusumab Phase III study in the upcoming months.

More details: Ultragenyx Pharmaceutical IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment